Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote & News

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanom...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 260 7120

Website: www.iovance.com

Address:

825 Industrial Road, Suite 100, San Carlos, United States

Joe521 Oct. 27 at 6:23 PM

$IOVA The demand is there. They need to be more selective and educate patients and physicians on benefits of early treatment. Iova is consistently losing 25-26% potential revenue due to patient drop and manufacturing failure. Huge room for improvement and needed for profitability. Move ASAP when frontline fails.

0 · Reply

Xanderzzzzzzz Oct. 27 at 6:17 PM

$IOVA

0 · Reply

UnderLion16 Oct. 27 at 5:41 PM

$IOVA https://www.linkedin.com/posts/iovance_please-join-us-in-supporting-the-melanoma-activity-7388605913240059904-mr0M?utm_source=share&utm_medium=member_desktop&rcm=ACoAAEsd0XQB-kbKVWH1Winw4qDcCWoIeyftplo

1 · Reply

StockednLoaded Oct. 27 at 5:29 PM

$IOVA - The min viable amount of TIL’s to be in-spec commercially is 5-6x > clinicals. This is not a scientific necessity but rather a regulatory and biz decision. Iova is punting near term rev bc it doesn’t matter. Apologies to all you margin watchers (and fudsters). It’s being strategically suppressed. By de-risking the launch (reducing product variability and in-field commercial failures) you protect LT value and brand. That’s why you’re seeing RW #’s trump clinicals’ bc on avg it’s superior product. ATC’s can administer OOS to help simulate operational flows at larger vols while keeping a governor on Rev. I bet they took a minimum TIL cell viability that is easily and routinely achievable in 1L since that’s all they care about mnfg at scale—and that’s why they’re partnering with McKesson bc eventually (once de-risked) the TIL commercial model becomes decentralized at the community level instead of closed-loop at the academic.

1 · Reply

beachsidefreddy Oct. 27 at 5:28 PM

$IOVA the jan $3 calls are offered at $.60 now thats up .20!!!!!!!!!!!!!

0 · Reply

tedevan Oct. 27 at 5:20 PM

$IOVA

0 · Reply

ZeroSumTeam Oct. 27 at 5:15 PM

$IOVA Big big move incoming Coiled and ready to pop $2.50-2.70 by end of week should be easy

0 · Reply

LostChang3 Oct. 27 at 5:15 PM

$IOVA so maybe the trick is to just not look at it on here ever. Then it might rise

0 · Reply

ECHorizon Oct. 27 at 4:59 PM

$IOVA Folks, what do you think? 🤔 IMO, it could be possible that the ESMO and SITC presentations are calculated to signal what’s coming. ESMO’s focus was on Amtagvi survival data (17-26% cure rates, 89-month lifetime OS) targets payers, while SITC’s focus is on efficacy - rash-efficacy link empowers clinicians, priming NSCLC/endometrial catalysts. ESMO (survival data for payers) + SITC (rash-efficacy for clinicians) = primed monster data/growth. Then the other items: $100M+ annual savings (announced Aug 7, via Q4 workforce/R&D cuts) will be in full effect soon/MFG efficiency gains to help improve margins/InspiroGene by McKesson partnership; plus IP moat (patents to 2044) secure TIL manufacturing. Long-term, If (a huge IF) catalysts hit, profitability could arrive by Q4 27 with $50M+ net income on expansions. Sustained profitability in 28 with $200M annual profits. A lot could go wrong, but it’s possible. 🤷‍♂️

0 · Reply

egolden08 Oct. 27 at 4:58 PM

$IOVA she looking thicc 😂

0 · Reply

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Oct 10, 2025, 10:30 AM EDT - 17 days ago

Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play

Aug 29, 2025, 8:30 AM EDT - 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences

Aug 21, 2025, 4:56 PM EDT - 2 months ago

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Aug 18, 2025, 4:15 PM EDT - 2 months ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 8, 2025, 3:15 AM EDT - 2 months ago

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Jul 23, 2025, 12:08 PM EDT - 3 months ago

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 18, 2025, 12:02 PM EDT - 3 months ago

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Jul 15, 2025, 7:30 AM EDT - 3 months ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 14, 2025, 9:04 AM EDT - 3 months ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 7:30 AM EDT - 3 months ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 11, 2025, 10:32 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 10, 2025, 4:01 PM EDT - 3 months ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 8:18 AM EDT - 3 months ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 3, 2025, 7:35 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 2, 2025, 5:46 PM EDT - 4 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

Jun 28, 2025, 7:46 AM EDT - 4 months ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 26, 2025, 4:45 PM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Jun 26, 2025, 9:00 AM EDT - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

Jun 24, 2025, 12:03 PM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jun 20, 2025, 9:07 AM EDT - 4 months ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 18, 2025, 2:34 PM EDT - 4 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

Jun 18, 2025, 8:38 AM EDT - 4 months ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 4 months ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 10, 2025, 8:47 AM EDT - 4 months ago

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

Jun 10, 2025, 8:45 AM EDT - 4 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

Joe521 Oct. 27 at 6:23 PM

0 · Reply

Xanderzzzzzzz Oct. 27 at 6:17 PM

$IOVA

0 · Reply

UnderLion16 Oct. 27 at 5:41 PM

1 · Reply

StockednLoaded Oct. 27 at 5:29 PM

1 · Reply

beachsidefreddy Oct. 27 at 5:28 PM

$IOVA the jan $3 calls are offered at $.60 now thats up .20!!!!!!!!!!!!!

0 · Reply

tedevan Oct. 27 at 5:20 PM

$IOVA

0 · Reply

ZeroSumTeam Oct. 27 at 5:15 PM

$IOVA Big big move incoming Coiled and ready to pop $2.50-2.70 by end of week should be easy

0 · Reply

LostChang3 Oct. 27 at 5:15 PM

$IOVA so maybe the trick is to just not look at it on here ever. Then it might rise

0 · Reply

ECHorizon Oct. 27 at 4:59 PM

0 · Reply

egolden08 Oct. 27 at 4:58 PM

$IOVA she looking thicc 😂

0 · Reply

Nibbler Oct. 27 at 4:51 PM

$IOVA Xbi screamin..... Iova...

1 · Reply

The_Scientist Oct. 27 at 4:45 PM

$IOVA Two cents higher—sound the horn, A legend in the market’s born. Raise your glass, oh mighty crowd, Two cents richer—say it loud.

2 · Reply

Revaluation Oct. 27 at 4:19 PM

$IOVA For the scientists out there - Are the commercial specs more stringent than the trial specs? If not, wouldn’t they have been running into this OOS issue for the past 5 years when producing treatment for trials? Seems like an odd thing to come out of nowhere and only affect the commercial product…

3 · Reply

KingNYC Oct. 27 at 4:10 PM

$IOVA They buy and it goes a bit up, they immediately pause it, and they let it go down and they buy more again. The loading game! Keep loading slowly to control the price to buy cheap before the big news breaks. The price must stay around here until this will pump to two digits.

0 · Reply

ZeroSumTeam Oct. 27 at 3:57 PM

$FUN $KRNT $JD $GPUS $IOVA LFG! 🔥 🐂 🆙

0 · Reply